ArticleBreast (Edinburgh, Scotland)2022

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Hiromichi Nakajima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.